Drug
Tazemetostat clinical trials
Also written EPZ-6438, E7438 and Tazverik.
- studies test it
- 41
- open now
- 1
- in phase 3
- 1
- first study started
- 2014
Keep track of what changes. Save the tazemetostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
41 studies that test it; most in 2023 (10)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 10 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 22
- Phase 2
- 25
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 24
Epizyme, Inc. (12) · National Cancer Institute (NCI) (6) · Weill Medical College of Cornell University (2) · Hutchmed (2) · Eisai Co., Ltd. (2) · City of Hope Medical Center (2) · Northwestern University (1) · The Lymphoma Academic Research Organisation (1)
Often tested with
Tested in the same studies.
Rituximab (3) · Pembrolizumab (3) · Lenalidomide (1) · Belinostat (1) · Ensartinib (1) · Erdafitinib (1) · Ivosidenib (1) · Larotrectinib (1)
Studies
Open first, then newest update. How each study uses tazemetostat is read from its arms, and is right about nine times in ten.
Testing it · 41
- Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal CarcinomaNot yet recruitingPhase 2Dr. Victor H.F. LeeNCT05151588Written as Tazemetostat
- Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03348631Written as Tazemetostat
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Active, not recruitingPhase 3Epizyme, Inc.NCT04224493Written as Tazemetostat
- Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentActive, not recruitingPhase 1National Cancer Institute (NCI)NCT05627245Written as Tazemetostat
- Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's LymphomaActive, not recruitingPhase 2Northwestern UniversityNCT06242834Written as Tazemetostat
- Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by ChemiotherapyActive, not recruitingPhase 1/2The Lymphoma Academic Research OrganisationNCT02889523Written as Tazemetostat
- Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial CarcinomaActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT03854474Written as Tazemetostat
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03155620Written as Tazemetostat
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell LymphomasActive, not recruitingPhase 1Weill Medical College of Cornell UniversityNCT05934838Written as Tazemetostat Pill
- Tazemetostat in Malignant Peripheral Nerve Sheath TumorsActive, not recruitingPhase 2University of FloridaNCT04917042Written as Tazemetostat
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPCActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT04846478Written as Tazemetostat
- Study of Tazemetostat in Lymphoid MalignanciesTerminatedPhase 1University of Alabama at BirminghamNCT05983965Written as Tazemetostat
- A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver FunctionTerminatedPhase 1Epizyme, Inc.NCT04241835Written as Tazemetostat
- Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsActive, not recruitingPhase 1/2Susan Chi, MDNCT05407441Written as Tazemetostat
- Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)CompletedPhase 2National Cancer Institute (NCI)NCT03213665Written as Tazemetostat
- Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin LymphomaTerminatedPhase 1Weill Medical College of Cornell UniversityNCT05618366Written as Tazemetostat
- Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A MutationTerminatedPhase 2Prisma Health-UpstateNCT05023655Written as Tazemetostat
- A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate CancerTerminatedPhase 1/2Epizyme, Inc.NCT04179864Written as Tazemetostat
- Combining Epigenetic And Immune Therapy to Beat Cancer.CompletedPhase 2Institut BergoniéNCT04705818Written as Tazemetostat
- A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular LymphomaActive, not recruitingPhase 1/2Vaishalee KenkreNCT05551936Written as Tazemetostat
See all 41 studies that test tazemetostat →
Given in every arm · 12 — tazemetostat is usual care beside what is tested
- A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate CancerRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT07407283Written as Tazemetostat
- Tazemetostat and Palbociclib With CPX-351for R/R AMLRecruitingPhase 1Thomas Jefferson UniversityNCT05627232Written as Tazemetostat
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentRecruitingPhase 2SWOG Cancer Research NetworkNCT05890352Written as Tazemetostat
- Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell LymphomaNot yet recruitingPhase 1/2Ruijin HospitalNCT07209163Written as Tazemetostat
- A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1/2Bristol-Myers SquibbNCT05372354Written as Tazemetostat
- Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04557956Written as Tazemetostat Hydrobromide
- Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT05353439Written as Tazemetostat Hydrobromide
- Tazemetostat and Mosunetuzumab in Untreated Follicular LymphomaActive, not recruitingPhase 2Weill Medical College of Cornell UniversityNCT05994235Written as Tazemetostat Pill
- Tazemetostat Plus CHOP in 1L T-cell LymphomaWithdrawnPhase 2Eric Jacobsen, MDNCT06692452Written as Tazemetostat
- Effects of Itraconazole and Rifampin on the Blood Tazemetostat LevelsCompletedPhase 1Epizyme, Inc.NCT04537715Written as Tazemetostat
- Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCLCompletedPhase 1/2Epizyme, Inc.NCT01897571Written as Tazemetostat
- A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.WithdrawnPhase 1/2Epizyme, Inc.NCT05205252Written as Tazemetostat
Codes
What other systems call tazemetostat · ClinicalTrials.gg INT000126
- MeSH (NLM) C000593333tazemetostatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Q40W93WPE1TAZEMETOSTATConfirmed FDA, NLM, Wikidata
- RxNorm 2274378One source FDA
- Wikidata Q27088941tazemetostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C107506TazemetostatOne source FDA
- DrugBank DB12887One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000593333 | tazemetostat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Q40W93WPE1 | TAZEMETOSTAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2274378 | — | One source FDA |
| Wikidata | Q27088941 | tazemetostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C107506 | Tazemetostat | One source FDA |
| DrugBank | DB12887 | — | One source Wikidata |
Also registered as tazemetostat dihydrobromide (UNII X536WKK41G), tazemetostat hydrobromide (UNII 6P89T5M073 · RxNorm 2274379), tazemetostat hydrochloride (UNII 1L6UQ905WM) and tazemetostat trihydrochloride (UNII 272LA4Y8S8).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.